132 results
Page 2 of 7
8-K
EX-99.1
nuodsumtl5
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
2ga3oi
9 Aug 23
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
q4h3643l0 284h
9 Aug 23
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
7:03am
8-K
7yi8so15vb9u69v
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
5:19pm
8-K
EX-99.1
uxbh5zdnvyv3 j5zkisp
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.2
mvgb1c
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.3
ojsfqyhe nrtbygn
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.1
qso7w
5 Jun 23
Regulation FD Disclosure
2:24pm
8-K
EX-99.2
jk1a0f4ly1texim ruk0
5 Jun 23
Regulation FD Disclosure
2:24pm
8-K
EX-99.1
f7w21q1ncu3 wyaa0
26 May 23
Regulation FD Disclosure
12:38pm
DEFA14A
xqk0n
10 May 23
Additional proxy soliciting materials
7:08am
PRE 14A
ecpzgj j9ah
18 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.1
sptp3knpxkbos3pkwpig
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
jm59b1h zs
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
EX-99.2
pxtpakzx34yugr
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am